Menu Search
Equities

Aspen Pharmacare Holdings Ltd

APN:JNB

Aspen Pharmacare Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ZAX)19,049.00
  • Today's Change-412.00 / -2.12%
  • Shares traded1.25m
  • 1 Year change+11.39%
  • Beta0.8267
Data delayed at least 15 minutes, as of Sep 18 2024 16:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform3
Hold2
Sell0
Strong Sell0

Share price forecast in ZAR

The 4 analysts offering 12 month price targets for Aspen Pharmacare Holdings Limited have a median target of 24,400.00, with a high estimate of 25,100.00 and a low estimate of 23,300.00. The median estimate represents a 28.09% increase from the last price of 19,049.00.
High31.8%25,100.00
Med28.1%24,400.00
Low22.3%23,300.00

Dividends in ZAR

In 2024, Aspen Pharmacare Holdings Ltd reported a dividend of 3.59 ZAR, which represents a 4.97% increase over last year. The 5 analysts covering the company expect dividends of 4.45 ZAR for the upcoming fiscal year, an increase of 23.82%.
Div growth (TTM)4.97%
More ▼

Earnings history & estimates in ZAR

Aspen Pharmacare Holdings Limited reported annual 2024 earnings of 14.92 per share on Sep 03, 2024.
Average growth rate+5.30%
More ▼

Revenue history & estimates in ZAR

Aspen Pharmacare Holdings Limited had revenues for the full year 2024 of 44.71bn. This was 9.82% above the prior year's results.
Average growth rate+3.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.